Benchmarking Framework for Performance-Evaluation of Causal Inference
  Analysis by Shimoni, Yishai et al.
Benchmarking Framework for Performance-Evaluation of Causal
Inference Analysis
Yishai Shimoni∗1, Chen Yanover†1, Ehud Karavani1, and Yaara Goldschmnidt1
1IBM Research - Haifa
March 21, 2018
Abstract
Causal inference analysis is the estimation of the effects of actions on outcomes. In
the context of healthcare data this means estimating the outcome of counter-factual treat-
ments (i.e. including treatments that were not observed) on a patient’s outcome. Compared
to classic machine learning methods, evaluation and validation of causal inference analy-
sis is more challenging because ground truth data of counter-factual outcome can never
be obtained in any real-world scenario. Here, we present a comprehensive framework for
benchmarking algorithms that estimate causal effect. The framework includes unlabeled
data for prediction, labeled data for validation, and code for automatic evaluation of algo-
rithm predictions using both established and novel metrics. The data is based on real-world
covariates, and the treatment assignments and outcomes are based on simulations, which
provides the basis for validation. In this framework we address two questions: one of scal-
ing, and the other of data-censoring. The framework is available as open source code at
https://github.com/IBM-HRL-MLHLS/IBM-Causal-Inference-Benchmarking-Framework
1 Introduction
Estimating the causal effect of an intervention on some measurable outcome (e.g. the effect
of a treatment or procedure on survival) is a vibrant field of research. It has gained much
traction in the last decade with the rise of big-data [1,2], especially in the context of health-care
(e.g., see [3–6]). Effect estimation from real-world observational data requires estimating all
counter-factual outcomes of a treatment (e.g. the outcome with and without treatment). This
estimation is complicated since for each individual we can only observe the factual outcome
associated with the treatment that was actually assigned to the individual.
One way of tackling this problem is through randomized controlled trials (RCTs). By
randomly assigning individuals to treatment groups it is possible to consider the average outcome
in each such treatment group as an unbiased estimate of the outcome in the entire population.
This allows calculating the average treatment effect in the population. However, RCTs are
labor- and time-intensive and, in some cases, may even by unethical or unfeasible. Additionally,
the population that is being recruited to an RCT is almost always pre-selected and does not
represent the global population. Finally, RCT-based estimates may also be biased, for example
when informative censoring occurs [7].
Estimating treatment effect from real-world observational data offers several advantages and
several drawbacks as compared to RCTs. On the one hand, such data represents much larger
and less homogeneous populations, and thus estimates based on such data are more immediately
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applicable to the general population and may also be available for rare diseases. On the other
hand, assignment of treatment typically depends on individual characteristics (e.g., the severity
of the disease), some of which may also affect the outcome of that same treatment, and therefore
introduce (confounding) bias. Correcting for such biases is required for an accurate estimation
of treatment effect. Indeed, many different methods have been devised for and applied to
this task, including inverse probability weighting (IPW) [8], g-formula [9], and doubly robust
methods [10].
Despite great advances in causal inference research, it is still unclear which algorithm should
be used for a given effect estimation instance. Moreover, it is unclear what data characteristics
(e.g. number of covariates or samples) need to be considered when selecting an algorithm and
how this affects performance. In part, this is due to a lack of common data sets and evaluation
measures that are used as agreed-upon benchmarks.
Many sub-fields of machine-learning have established benchmarking datasets that allow
comparisons between methods. Such datasets exist, for example, for handwriting recognition
[11], object detection [12], and sentiment analysis in natural language processing [13], among
others. However, no such benchmarking dataset exists for causal inference analysis.
Here we present a comprehensive framework for offline benchmarking of methods for causal
effect inference, called the IBM Causal Inference Benchmarking Framework, which is available
online as open-source code. The framework contains a python package that allows evaluation of
the estimated effects by providing several non-redundant scores. This evaluation can be applied
to any given set of ground-truth data and inference data. Specifically, the framework includes
a dataset, as detailed below, that can allow a standardized comparison using a unified dataset
and a unified evaluation code.
Since individual ground-truth data of causal effect can never be known for any real-world
treatment, we developed a simulation-based approach that uses a set of covariates and creates
a causal graph to determine treatment assignment and effect. The framework contains multiple
pairs of simulated treatment assignments and effects, and their associated ground-truth counter-
factual data (i.e. the outcome for each value of the treatment assignment). To ensure that the
evaluated performance has real-world implications we used a cohort of 100K samples derived
from the publicly available Linked Births and Infant Deaths Database (LBIDD) [14] as the
fundamental set of covariates.
The data is divided into two sets, each aimed to answer a different question related to
large real-world observational data. The first question is one of scaling - can a method take
advantage of increasing data sizes, and at what computational cost? To answer this question, we
include data sub-sets comprised of files with varying sizes. The performance on each size can be
evaluated separately and a global score can be calculated, summarizing the performance of the
method on the whole data set. The second question is regarding informative censoring - what
methods perform better when outcome is missing for a non-random subset of the samples? Such
a scenario may arise, for example, when a treatment is very effective and as a result there is no
follow-up, or when a treatment has severe side-effects and therefore for some of the individuals
we do not observe the results of the treatment. To address this question, we include data
sets in which some of the outcomes are replaced by an NA value according to some underlying
pre-determined model (built on top of the features).
In both sets, each simulation file is associated with meta-data indicating the type of simula-
tion that generated it. This includes information such as the number of covariates, the number
of confounding covariates (that affect both treatment assignment and outcome), and the lev-
els of non-linearity. This information can be used to further analyze the variables affecting
performance.
The scoring code is in Python (versions 2.7 or ≥ 3.4) and is publicly available as an open-
source (Apache 2.0 license) github repository at https://github.com/IBM-HRL-MLHLS/IBM-
Causality-Benchmarking-Framework. A full usage description is available in the code repository.
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2 Methods
2.1 Notation
There are several ways to define causal effect [15]. Let us define the counter-factual outcome for
individual i as the outcome that might be observed had they received treatment a, denoted by
yai . In the context of this benchmarking platform we use the additive treatment effect, which
is the difference between the treated and untreated counter-factual outcomes. Therefore, the
individual treatment effect for individual i is defined as y1i − y0i , where a = 1 denotes treatment
and a = 0 denotes no-treatment. The average of the individual treatment effect across the whole
population is defined as the population treatment effect, or average treatment effect (ATE) [16].
2.2 Data Description
The data is conceptually comprised of three main components:
• Covariate table: A table holding features in the columns and samples (i.e. individuals) in
rows, and serves as the basis for all the simulated observed outcomes. The data is based
on real-world clinical measurements taken from the Linked Birth and Infant Death Data
(LBIDD) [14].
• Factual outcome files (observation files): A set of three-column files containing sample
id, simulated treatment assignment, and simulated observed outcome. This emulates the
clinical data that may be available in real-world observational databases.
• Counter-factual outcome files (label files): A set of files containing sample id, simulated
outcome without treatment, and simulated outcome with treatment. These files serve as
the labeled data and used for evaluating the prediction results.
The covariate file is named x.csv, and is a comma-delimited-file with a header as its first
row holding the names of the features. The covariate file is used to create the observation and
label files as explained below. Each sample (row) in the covariates file has a unique sample id
to match the corresponding sample id in the observation data and in the label files (since these
files contain fewer samples than available in the covariate file).
A schematic of the data-flow is provided in Figure 1, describing the following steps. First, a
data generating process (DGP) is defined to generate simulated counter-factual outcome values
from the covariate file. The DGP is defined by a collection of parameters that determine the
complexity of the causal graph, as well as the functions defining the functional relation between
the covariates and the outcome, as explained in Section 2.5.
Once a DGP is defined, a specific instance of the DGP is used (i.e. a model is created that
adheres to the comlpexity parameters above) to create counter factual outcomes, from which the
label file and the observations file are created. Such a pair is denoted as a data instance. Each
DGP is used multiple time to create DGP instances, and each one create one data instance,
where each data instance is based on a sub-group of samples from the covariates file.
The data is conceptually split into two evaluation tracks: one for the evaluation of perfor-
mance as a function of size (scaling directory), and one for the evaluation of performance
in the presence of censored data (censoring directory). In the scaling evaluation track there
are files containing n samples each, where n ∈ {1k, 2.5k, 5k, 10k, 25k, 50k}. In the censoring
evaluation track each file contains 10k samples.
In order to discourage reverse-engineering (e.g. to determine which data comes from which
DGP), each file pair has a unique file identifier (ufid) u (e.g. 8c5f509) as its base name which
is unrelated to the DGP. The factual files are named using the base name followed by a .csv
extension (e.g. 8c5f509.csv), and are comma-delimited files (with a header) containing the
sample id, z, and y, where z is the treatment assignment and y is the observed outcome (NA is
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Figure 1: A schematic of the data-flow in the benchmarking platform. (A) Covariate data is
provided and a subset of samples is randomly selected. (B) A data generating process (DGP)
is applied using the selected subset in order to create the files containing the counter-factual
outcomes (label files). The observation files are created by only selecting the relevant counter-
factual outcome (or providing an NA value when censored). (C) The prediction algorithm can
be trained using pairs of observation and label files. For testing and evaluation, the prediction
algorithm uses the observation files to create effect prediction estimations, which are compared
with the label files to obtain the scoring metrics.
used as the outcome in case of censoring). The counter-factual files are named using u followed
by cf.csv suffix (e.g. 8c5f509 cf.csv), and are also comma-delimited files (with a header)
containing the sample id, y0, and y1.
2.3 Output Data Description
Regardless of the evaluation track (i.e. scaling or censoring), results can be evaluated either for
population effect prediction or individual effect prediction.
Population effect prediction requires estimating three values per observed data file: (a) the
effect size over the population, (b) the left boundary of a 95% confidence interval, and (c) the
right boundary of a 95% confidence interval. Therefore, all estimates for all instances of provided
observed data can fit into one comma-delimited file where each row represents a different data
instance u indicated in the first column, followed by one column for each estimated value above.
The evaluation code assumes a header line (holding ufid, effect size, li, ri), and does not
impose any restrictions on the order of data instances used.
Evaluation of individual effect requires two estimates for each individual i in each observed
data instance u: the predicted outcome without treatment (y0i ), and the predicted outcome
with treatment (y1i ). Consequently, for each data instance u, there should be a corresponding
comma-separated file named u.csv. In this file, each row corresponds to an individual from
the observed data instance (by matching the sample id key). Each row has three columns:
sample id of the same individuals from the observation file, and two other columns, namely y0
and y1, for the estimated counter-factual outcomes y0 and y1, respectively. All these comma-
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separated files should be placed in a single directory in order for the evaluation script to evaluate
them all. Please refer to the green panel in Fig 1C.
2.4 Scoring
The benchmarking framework provides several non-redundant scoring metrics that together
allow a comprehensive and comparative estimation of the performance of each method.
Metrics are calculated separately for each given size of dataset and are later aggregated. It
is possible to provide only a subset of the sizes as input to the scoring code (e.g. if the running
time becomes prohibitive), and obtain scores for the submitted sizes only.
Let n ∈ {1k, 2.5k, 5k, 10k, 25k, 50k} be the number of samples in a data instance. We denote
Dn to be the set of all the data instances consisting of n samples. let the true effect size be e
and the estimated effect size eˆ. The main score is based on the accuracy of the point-estimated
effect. For the population-effect predictions, where the 95% confidence interval (CI) is provided,
several additional metrics based on the CI are included to evaluate the precision of methods as
well.
2.4.1 ENoRMSE Score
Accuracy is measured on the estimated effect size using effect-normalized root mean squared
error (ENoRMSE). This is done since the size of the error, as measured by the bias eˆ − e,
depends on the actual effect (i.e. a large bias for a large effect should count the same as a small
bias for a small effect). The ENoRMSE score for the population effect predictions for a specific
Dn is defined as
En =
√√√√ 1|Dn|
∑
j∈Dn
(1− eˆj
ej
)2, (1)
where we add a stabilization constant of δ = 10−7 in both numerator and denominator to avoid
division by zero errors.
In a similar way, for individual effect prediction, the ENoRMSE score is calculated in the
following way. For each individual i ∈ {1, ..., n} in a data instance j we first obtain the estimated
individual effect, ˆei,j = Yˆ
1
i,j − Yˆ 0i,j . We then obtain the true individual effect from the simulated
counter-factual values ei,j = Y
1
i,j − Y 0i,j . The ENoRMSE accuracy metric is then defined as
En =
√√√√ 1
|Dn|
∑
j∈Dn
1
n
n∑
i=1
(1− ˆei,j
ei,j
)2, (2)
where here, too, we add a stabilization factor δ in both parts of the fraction.
RMSE Score Since ENoRMSE might be sensitive to small effect-sizes and since computa-
tional precision tends to decrease near zero, the ENoRMSE score might over-penalize estima-
tions for cases with no effect. We therefore add the framework the standard (a.k.a vanilla)
un-normalized root mean square error calculation:
RMSEn =
√√√√ 1|Dn|
∑
j∈Dn
(eˆj − ej)2. (3)
2.4.2 Bias
The above accuracy measures square the estimation error, leaving no information regarding the
direction of error. Bias measures the difference between the estimated effect and the true one.
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Allowing us to later examine whether certain algorithms tend to over-estimate or under-estimate
causal effect.
Bn =
1
|Dn|
∑
j∈Dn
(eˆj − ej). (4)
2.4.3 Coverage
Coverage is calculated as the percentage of times the estimated confidence interval (CI) of the
effect size covered the true effect size, and is defined by
Cn =
1
|Dn|
∑
j∈Dn
1[lj≤ej≤rj ], (5)
where 1A is the indicator function (i.e. equals to 1 if x is true and 0 otherwise), and lj and rj
are the left and right edges of the CI, respectively.
Coverage is a non-parametric estimation of the CIs. It offers an intuitive measure of the
reliability of the method, but only if the CIs are calculated correctly and genuinely. For example,
if a method grossly underestimates its CI then its coverage will not be comparable with another
method that overestimates its CI. Additionally, coverage is also prone to misleading results and
to hacking, (e.g. providing CIs that are (−∞,∞) guarantees full coverage, but this result is
non-informative).
2.4.4 CIC
Confidence-interval credibility (CIC) estimates the reliability of the CI. It is defined as
ξn =
1
|Dn|
∑
j∈Dn
|eˆj − ej |
rj − lj . (6)
The CIC provides an estimate of the percentage of times when the real value is within
the confidence interval. It captures the average ratio between the CI and the actual error. In
general, if the CI reliably calculates the 95% CI, then this value should approach 0.95 (except for
some pathological cases). As a result, if the CIC is too far from unity then the CI is unreliable,
and the coverage should be ignored.
2.4.5 ENCIS
The effect normalized confidence interval size (ENCIS) measures the effective size of the 95%
confidence interval. The smaller the CI size - the more precise the estimation is. However, as
with the ENoRMSE score, we normalize by the effect size since larger CI can be tolerated for
large effect sizes. The ENCIS is defined as
n =
1
|Dn|
∑
j∈Dn
rj − lj
|ej | . (7)
Here too, like in the ENoRMSE score, we add a stabilization term in the numerator and de-
nominator.
2.4.6 Aggregating Scores
In the scaling evaluation track scores are obtained for each dataset size n ∈ {1k, 2.5k, 5k, 10k,
25k, 50k} individually, as described above. To obtain a single score all the individual scores are
aggregated so that each sample carries an equal weight. This implies that larger datasets carry
a larger weight in the overall aggregated score, as desired.
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Let An be a squared accuracy score (i.e. ENoRMSE and RMSE) for given Datasets of size
n as defined in Eq. 1 and Eq. 3. The aggregated score is a weighted quadratic sum of the form
E =
√
1∑
n n|Dn|
·
∑
n
n|Dn| · E2n. (8)
For all other precision scores Pn (i.e. the Coverage, CIC, ENCIS and the non-squared
accuracy score Bias) the aggregated score is a weighted sum of the form
P =
1∑
n n|Dn|
·
∑
n
n|Dn| · Pn. (9)
2.5 Data Generation
The simulation algorithm is designed to use a causal graph to determine the functional relation
between a set of covariates and a resulting simulated node (i.e. treatment assignment, outcome,
and censoring decision). Once this graph is defined, the data is used to calculate the values of
the simulated nodes.
The causal graphs themselves are chosen randomly according to a set of parameters. Each
such set of parameters defines a data-generating process (DGP), and given a random seed, each
DGP can provide a data instance pair of counter-factual results and factual results.
Parameters include the number of covariates controlling each simulated node and how many
of them overlap (i.e. affect more than one node). Specifically, a set of features is randomly
chosen and connected to the outcome node; another set of features is chosen and connected to
the treatment assignment node; and another set of features (possibly including the treatment
assignment) is connected to the censoring node. These nodes act in unison to determine the
factual results that are reported. Specifically, both counter-factual outcomes, censoring, and
treatment assignment are first calculated. Then, if censoring is true then a value of NA is reported
as the observed outcome. Otherwise, depending on the value of the treatment assignment, the
corresponding counter-factual outcome is reported. To ensure that our simulation mimics a
situation with no unmeasured confounders we do not use additional simulated data and share
all the covariates the DGPs were based upon. Other parameters define treatment prevalence (i.e.
percentage of treated); the amount of noise in the system (e.g. heterogeneity of treatment effect
[17]); and the degree of non-linearity between a simulated variable and it’s causing covariates
(i.e. the degree of the polynomial, whether to use an exponential transform, etc.).
It should be noted that the code for simulating the data is currently not part of the bench-
marking framework. This is because the framework was chosen to be used in the causal inference
challenge, as part of the Atlantic Causal Inference Conference (ACIC2018). Details on the chal-
lenge can be found at https://www.cmu.edu/acic2018/data-challenge.
3 Discussion and Conclusion
We presented here a comprehensive benchamrking framework for the evaluation of methods
for causal inference of treatment effects. The framework includes covariate data, simulated
treatment assignment, simulated counter-factual outcomes, and code for evaluation of estimated
effect. The framework is distributed freely using Apache 2.0 license on github.com.
We believe that, like in other fields of research, such benchmarking platforms can allow a
better comparison between methods, including the limitations and advantages of each method.
This will allow the community to jointly identify potential pitfalls and the areas most deserving
effort.
We note also that there is no need to be confined to the data we provided, and individuals
can still use the evaluation code with their own data. Furthermore, since the data and code
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reside on github, important contributions can be suggested by the community. We encourage
the community to work with us to contribute additional data-sets, and welcome suggestions for
more benchmarking metrics. Such suggestions may be incorporated into the framework and be
available to the community as a new version of the benchamrking framework.
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